• Accelerating TB vaccine Research & Development through partnership
  • TBVI TBVI TBVI
    • Home
    • About us
      • TBVI at a glance
      • Mission
      • Organisation
        • Governance Board
        • Advisory Committee
        • Steering Committee
        • Operational Office
        • Product and Clinical Development Team
        • Portfolio Management Committee
      • TBVI consortium
      • Key achievements and impact
      • Financials
      • Policies
    • What we do
      • Pipeline of vaccines
      • Research & Development
      • Services
    • How we work
      • Business model
      • Partnership
    • For partners
      • For researchers and vaccine developers
        • Partners pages
        • Access to services
      • MTBVAC in Newborns
        • Coordinator and partners
        • News and Publications
        • Communication tools
      • MTBVACN3
        • Work packages
        • Governance
        • The consortium and its partners
        • Publications and news
        • Acknowledgement
      • TBVAC2020
        • Word from the chair
        • TBVAC2020 project overview and achievements
        • TBVAC2020 project members
        • TBVAC2020 scientific publications
        • TBVAC2020 other publications
      • For funders
        • TBVI R&D priorities and funding opportunities
        • TBVI service provision and funding opportunities
        • Why invest in TBVI
    • News
    • Contact us:

    Sitemap

    Home / Sitemap
    • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone di Palermo (AOUP)
    • Contact us:
    • High Level Event – 11th May 2017 – Brussels
    • MTBVACN3 Projectmeeting – Madagascar
    • Press release BIOFABRI and BHARAT BIOTECH
    • Press release BIOFABRI and BHARATBIOTECH
    • Registration for TBVI meeting in Les Diablerets, Switzerland
    • Registration Kick off meeting MTBVACN3 in Spain from10 – 12 May 2020
    • Registration MTBVAC in Newborns meeting – Madagascar – 27-28 May 2020
    • Registration MTBVAC in Newborns meeting – Senegal
    • Registration TBVI annual meeting April 2022
    • Registration TBVI annual meeting Les Diablerets 2018
    • Registration TBVI annual meeting Les Diablerets 2019
    • Registration TBVI meeting in Les Diablerets 2020
    • Registration Workshop 8 October 2019 in Brussels: “Maintaining European scientific excellence and global leadership in TB Vaccine R&D”
    • TBVI Annual meeting 3 – 6 April 2023 – Les Diablerets, Switzerland
    • TBVI meeting “Accelerating the TB vaccine pipeline – towards Horizon Europe – Les Diablerets, Switzerland
    • TBVI meeting 2022 – Les Diablerets, Switzerland
    • Vacancy Project Manager at SATVI – Cape Town, South Africa
    • World TB day 2018
    • Home
    • Centre National de la Recherche Scientifique – CNRS
    • ETH-Zürich – Institute of Molecular Systems Biology
    • Friedrich-Loeffler-Institute
    • About us
      • TBVI at a glance
      • Mission
      • Organisation
        • Advisory Committee
        • Steering Committee
        • Operational Office
        • Product and Clinical Development Team
        • Portfolio Management Committee
        • Governance Board
      • TBVI consortium
      • Key achievements and impact
      • Financials
      • Policies
    • Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)
    • Imperial College – TB research group Section for Paediatrics
    • What we do
      • Pipeline of vaccines
      • Research & Development
      • Services
    • International Tuberculosis Research Center (ITRC)
    • IRCCS Lazzaro Spallanzani
    • Leiden University Medical Centre (LUMC)
    • How we work
      • Business model
      • Partnership
    • London School of Hygiene and Tropical Medicine (LSHTM)
    • Medical Research Council – The Gambia Unit
    • NIBSC/MHRA
    • SATVI – University of Cape Town
    • Scientific Institute for Public Health (WIV-ISP)
    • Statens Serum Institute
    • Stellenbosch University
    • For partners
      • For researchers and vaccine developers
        • Partners pages
        • #7788 (no title)
        • Access to services
      • MTBVAC in Newborns
        • Communication tools
        • News and Publications
        • Coordinator and partners
      • MTBVACN3
        • Acknowledgement
        • Governance
        • Publications and news
        • The consortium and its partners
        • Work packages
      • TBVAC2020
        • Word from the chair
        • TBVAC2020 project overview and achievements
        • TBVAC2020 project members
        • TBVAC2020 scientific publications
        • TBVAC2020 other publications
      • For funders
        • TBVI R&D priorities and funding opportunities
        • TBVI service provision and funding opportunities
        • Why invest in TBVI
    • Université Libre de Bruxelles
    • University Hospital of Ulm
    • University of Cape Town
    • University of Lausanne, Vaccine Formulation Laboratory
    • University of Oxford, the Jenner Institute
    • University of Sydney
    • University of Zaragoza
    • Yonsei University College of Medicine
    • News & events
      • News
      • Events

    Menu
    • Home
    • About us
    • What we do
    • How we work
    • For researchers and vaccine developers
    • For funders
    • Pipeline of vaccines
    • News
    TuBerculosis Vaccine Initiative (TBVI)

    Runderweg 6
    8219 PK Lelystad
    The Netherlands
    Email: info@tbvi.eu
    Phone: +31 320 277 550

    © 2015 TuBerculosis Vaccine Initiative (TBVI) | ALL RIGHTS RESERVED | Disclaimer | Sitemap | Door Internetbureau Redkiwi

    Start typing and press Enter to search

    Cookies

    This website uses cookies that help the website function

    OK No